Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology (NASDAQ: PYXS), a clinical-stage company focused on developing next-generation ADC therapeutics for difficult-to-treat cancers, has announced its participation in two upcoming investor conferences. The company's President, CEO, and CMO, Dr. Lara S. Sullivan, will engage in fireside chats at:
- The 2025 RBC Capital Markets Global Healthcare Conference in New York on May 21 at 2:05 p.m. ET
- The Jefferies Global Healthcare Conference in New York on June 5 at 4:55 p.m. ET
Investors can access live webcasts and replays of both presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website.
Pyxis Oncology (NASDAQ: PYXS), un'azienda in fase clinica specializzata nello sviluppo di terapie ADC di nuova generazione per tumori difficili da trattare, ha annunciato la sua partecipazione a due prossimi convegni per investitori. La Presidente, CEO e CMO dell'azienda, la Dott.ssa Lara S. Sullivan, parteciper脿 a colloqui informali nei seguenti eventi:
- La 2025 RBC Capital Markets Global Healthcare Conference a New York il 21 maggio alle 14:05 ET
- La Jefferies Global Healthcare Conference a New York il 5 giugno alle 16:55 ET
Gli investitori potranno seguire le dirette streaming e le registrazioni di entrambe le presentazioni nella sezione Eventi e Presentazioni della pagina Relazioni con gli Investitori sul sito web di Pyxis Oncology.
Pyxis Oncology (NASDAQ: PYXS), una empresa en etapa cl铆nica enfocada en desarrollar terapias ADC de pr贸xima generaci贸n para c谩nceres dif铆ciles de tratar, ha anunciado su participaci贸n en dos pr贸ximas conferencias para inversores. La presidenta, CEO y CMO de la compa帽铆a, la Dra. Lara S. Sullivan, participar谩 en conversaciones informales en:
- La Conferencia Global de Salud de RBC Capital Markets 2025 en Nueva York el 21 de mayo a las 2:05 p.m. ET
- La Conferencia Global de Salud de Jefferies en Nueva York el 5 de junio a las 4:55 p.m. ET
Los inversores podr谩n acceder a transmisiones en vivo y repeticiones de ambas presentaciones a trav茅s de la p谩gina de Eventos y Presentaciones en la secci贸n de Relaciones con Inversores del sitio web de Pyxis Oncology.
Pyxis Oncology (NASDAQ: PYXS)電� 旃橂臧� 鞏措牑鞖� 鞎旍潉 鞙勴暅 彀劯雽� ADC 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠 旮办梾鞙茧, 霊� 臧滌潣 雼り皜鞓る姅 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 靷灔 瓴� CEO, CMO鞚� 霛茧澕 S. 靹るΜ氩� 氚曥偓電� 雼れ潓 頄夓偓鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�:
- 2025雲� 5鞗� 21鞚� 鞓ろ泟 2鞁� 5攵�(霃欕秬鞁滉皠) 雺挫殨鞐愳劀 鞐措Μ電� RBC 旌愴敿韮� 毵堨紦 旮�搿滊矊 項姢旒�鞏� 旎嵓霟办姢
- 2025雲� 6鞗� 5鞚� 鞓ろ泟 4鞁� 55攵�(霃欕秬鞁滉皠) 雺挫殨鞐愳劀 鞐措Μ電� 鞝滍嵓毽姢 旮�搿滊矊 項姢旒�鞏� 旎嵓霟办姢
韴瀽鞛愲摛鞚� Pyxis Oncology 鞗轨偓鞚错姼鞚� 韴瀽鞛� 甏�瓿� 靹轨厴 雮� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴 韼橃澊歆�毳� 韱淀暣 霊� 氚滍憸 氇憪鞚� 霛检澊敫� 鞗轨簮鞀ろ姼鞕� 鞛癌靻§潉 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Pyxis Oncology (NASDAQ: PYXS), une soci茅t茅 en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapeutiques ADC de nouvelle g茅n茅ration pour les cancers difficiles 脿 traiter, a annonc茅 sa participation 脿 deux prochaines conf茅rences pour investisseurs. La Pr茅sidente, CEO et CMO de l'entreprise, le Dr Lara S. Sullivan, participera 脿 des discussions informelles lors de :
- La Conf茅rence mondiale sur la sant茅 RBC Capital Markets 2025 脿 New York le 21 mai 脿 14h05 ET
- La Conf茅rence mondiale sur la sant茅 Jefferies 脿 New York le 5 juin 脿 16h55 ET
Les investisseurs pourront acc茅der aux webdiffusions en direct et aux replays des deux pr茅sentations via la page 脡v茅nements & Pr茅sentations dans la section Relations Investisseurs du site web de Pyxis Oncology.
Pyxis Oncology (NASDAQ: PYXS), ein klinisch fortgeschrittenes Unternehmen, das sich auf die Entwicklung von ADC-Therapeutika der n盲chsten Generation f眉r schwer behandelbare Krebsarten spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angek眉ndigt. Die Pr盲sidentin, CEO und CMO des Unternehmens, Dr. Lara S. Sullivan, wird an folgenden Fireside-Chats teilnehmen:
- Auf der 2025 RBC Capital Markets Global Healthcare Conference in New York am 21. Mai um 14:05 Uhr ET
- Auf der Jefferies Global Healthcare Conference in New York am 5. Juni um 16:55 Uhr ET
Investoren k枚nnen Live-Webcasts und Wiederholungen beider Pr盲sentationen 眉ber die Seite Events & Presentations im Investor Relations-Bereich der Pyxis Oncology-Website abrufen.
- None.
- None.
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences.
- 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ET
- Jefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET
A live webcast and replay of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology鈥檚 website, .
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck鈥檚 anti-PD-1 therapy, KEYTRUDA庐聽(pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.
To learn more, visit聽聽or follow us on聽听补苍诲听.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
FAQ
What investor conferences will Pyxis Oncology (PYXS) attend in May and June 2025?
Who will represent Pyxis Oncology (PYXS) at the 2025 investor conferences?
How can investors access Pyxis Oncology's (PYXS) conference presentations?
What type of therapeutics is Pyxis Oncology (PYXS) developing?
